LCS101 protection from Chemotherapy side effects
The protective properties of LCS101 were tested in a randomized, controlled, double blind clinical trial that was conducted on breast cancer patients at the Sourasky (Ichilov) Medical Center, in Tel-Aviv, Israel. All patients had been diagnosed with localized tumors and referred to chemotherapy before they were included in the study.
The patients were randomized to receive either chemotherapy with LCS101 or chemotherapy with a placebo.
The interventions (LCS101 or Placebo) were started two weeks prior to the first chemotherapy dose and continued until the last dose. Neither the patients nor the medical staff were aware of who was on the placebo and who was on LCS101, following the double-blind protocol.
This study focused on the rates of anemia and leukopenia, and showed that 82% of patients who took LCS101 did not suffer from a decrease of white blood cells (WBC) or red blood cells (RBC) counts.
Publisher: The Oncologist Journal
Click here for the full publication.
An additional clinical trial tested the effect of LCS101 on chemotherapy side-effects in breast cancer patients.
89% of the patients reported LCS101 improved their quality of life and helped reduce their symptoms such as fatigue, weakness, pain, nausea, vomiting and decreased appetite.
Publisher: Integrative Medicine Insights Journal
Click here for the full publication.
LCS101 Anti-Cancer effect
The selective killing effect of LCS101 was tested in pre-clinical trials (in vitro).
The aim of the study was to examine the selectivity of the effects of the compound, alone and in conjunction with conventional chemotherapy agents, on cancer cells.
The study demonstrated that the formula actively destroys breast, colon and prostate cancer cell lines. The formula was also shown to protect normal cells from the damages associated with chemotherapy, and potentiating the cancer cells to the treatment.
Publisher: International Journal of Oncology
Click here for the full publication.
LCS101 Immunological effect
The effect of LCS101 on various components of the immune system was evaluated in a pre-clinical trial. The study focused on the potential role of LCS101 in immune system stimulation.
The results suggest that LCS101 has an immune-modulating capacity – as evidenced by improvement in both adaptive and innate immunity.
Publisher: OncoTargets and Therapy
Click here for the full publication.
LCS101 interaction with chemotherapy
The research included pre-clinical studies conducted with a chemotherapy testing dose and time dependent interaction with on over 10 different type of cancers and 10 different types of chemotherapy.
The findings of the study showed that the botanical formula LCS101 does not reduce the cytotoxic effects of multiple chemotherapy agents. Instead, the addition of LCS101 led to increased death of cancer cells from the chemotherapy agents.
Publisher: Journal of Cancer Science & Therapy
Click here for the full publication.
LCS101 effect on anti cancer effect of Radiation therapy
This pre-clinical study examined the interaction between LCS101 and radiation therapy on cancer cell lines where incremental doses of LCS101 were added to 5 types of cell lines 4 hours after single-dose of radiation.
The addition of the botanical formula LCS101 to irradiated cancer cells results in an apparent additive effect, most likely through a ROS-mediated mechanism. These findings support the use of LCS101 by patients undergoing radiation therapy, for both its clinical as well as anti-cancer effects.
Publisher: Journal of Cancer Research and Clinical Oncology
Click here for the full publication.